The purpose o f this study was to develop sustained-release tablets o f diltiazem HC1 using alkali-treated guar gum as a hydrophilic matrixing agent.
an undesirable drug release rate. The nsk of unpredicted drug delivery could be reduced by using swellable hydrophilic matrix systems.
Hydrophilic matrix tablets swell upon ingestion and a gel layer forms on the tablet surface. This gel layer fills interstices within the tablets, which retards further ingress o f fluid and subsequent drug release. The dissolution rate for soluble drugs is controlled by both diffusion through the gel layer and by matrix erosion, whereas the dissolution rate for insoluble drugs is strictly dependent on matrix erosion.
O f the various types o f matrixing agents for oral sustained-release tablets, cellulose ethers are the most extensively investigated. Natural materials such as alginates, carrageenan, ispagula husk and guar gum are promising matrix carriers for obtaining sustained drug release because they are relatively inexpensive, non-toxic and easily available.
Guar gum is an interesting adjuvant for the pre paration of hydrophilic matrix tablets because of its unique properties such as swelling, gel formation, non-toxicity and biodegradability. It is significantly less expensive than hydroxypropylmethylcellulose (HPMC) and other cellulose derivatives. Guar gum is found in the seeds of the Cyamopsis tetragonolobus. It is a galactomannan poly saccharide consisting of linear chains of (1-4)-/1-dmannopyranosyl units and a-D-galactopyranosyl units attached by (1) (2) (3) (4) (5) (6) linkages. The ratio of D-galactose to D-mannose is 1 :2 (Yu et al 1996). Guar gum typically contains about 80% galacto mannan, 12% water, 5% protein, 2% acid-insoluble matter and 1% fat Of the 80% galactomannan, approximately 52% is soluble galactomannan and 28% is insoluble galactomannan (Gebert & Friend 1998) .
Guar gum is used as a viscosity modifier, a binder of free water, a suspending agent, a stabilizer and a source of dietary fibre. In the pharmaceutical and cosmetic industries, this non-iomc polymer is pri marily used as a disintegrant (Dura 1992 We have recently reported that guar gum based tablets show slow drug release (Gohel et al 1998) . A thin gel layer formation compared with that of other water-soluble polymers (Takai et al 1984) , an uncontrolled rate of hydration and a high intrinsic viscosity (Misra & Baweja 1997 ) limits the use of guar gum as a sustained-release agent. This study was undertaken to develop modified guar gum for use as a matrixing agent to obtain uniform drug release.
Diltiazem H Q , a calcium-channel blocker, is widely prescribed for the treatment of angina pec toris, arrhythmias and hypertension. Its high aqu eous solubility, short elimination half-life (3 -5 h) and use in chronic diseases, make it a suitable candidate for sustained-release dosage forms (Khan 1995) .
Statistical design is an efficient method for establishing the relative significance of a number of variables and their interactions. In this study, a uniform precision rotatable central composite design was adopted for optimizing the matrix tablet formulation of diltiazem HC1 containing modified guar gum
Materials and Methods

M a terials
Diltiazem HC1 USP and HPMC K4M were gener ous gifts from Cadila Health Care Pvt. Ltd. Guar gum IP (5400 cPs viscosity, 2% w/v) was a gift from H. B. Gum Industries Ltd. Magnesium stea rate IP, talc IP and succinic acid were used as received. All the other solvents and chemicals were of analytical grade and were used without further purification. Deionized double-distilled water was used throughout the study.
Assay
Aqueous solutions of diltiazem HC1 in distilled water were prepared and the absorbance was measured at 237 nm using a Hitachi U-2000 U VVis double-beam spectrophotometer. An equation was generated by fitting a weighted linear regres sion model to the data obtained in triplicate ).
Modification o f guar gum
A 1% w /v aqueous NaOH solution (500 mL) was mixed with a blend of 100 g guar gum and 100 mL water. The resultant mixture was heated at 60°C for 3 h. After cooling to room temperature (30°C), the semisolid mass was neutralized with dilute acetic acid and then treated with acetone (about 800 mL). The resulting mass was washed with acetone and dried in a hot-air oven at 60°C to a constant weight. The powdered modified guar gum (No. 100/120) Swelling capacity is represented as means ± s .e , n = 3.
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was stored in a glass jar before use A control batch was prepared containing guar gum (100 g) mixed with water (600 mL), heated at 60°C for 3 h and then treated with acetone (approx. 600 mL). To study the influence o f reaction conditions on swelling capacity, an additional eight batches were prepared according to the design shown in Table 1 . The swelling study of untreated guar gum and modified guar gum was carried out by the method outlined by Bowen & Vadino (1984) . The swelling capacity was calculated by taking the ratio of swollen volume to bulk volume after storing 1 g gum in 100 mL water for 24 h at room temperature (n = 3).
Preparation o f tablets (preliminary trials)
Diltiazem HC1 (45 g) and either untreated guar gum or modified guar gum (batch C, 56-25 g) were blended and then an aqueous solution of HPMC K4M (2-5% w /v) was gradually added as a binding agent with continuous mixing. The wet homo geneous mass was sieved through a No. 22 sieve. The granules were dried in a hot-air oven at 60°C for 3 h. The dried granules were sieved through a
No. 30 sieve, lubricated with 2% w /w magnesium stearate and 1% w /w talc. The tablets were pre pared on a rotary tablet press equipped with con cave punches o f 7-mm diameter to produce tablets with hardness of 5 -0 ± 0 -5 k g c m -2 . The average weight and drug content o f the tablet were 210 and 90 ± 5 mg, respectively.
Dissolution study
In-vitro release of diltiazem HC1 from the matrix tablets was measured according to USP 23 paddle apparatus at 37± 0-5°C and at 50 rev m in-^ using 900 mL distilled water as a dissolution medium (n = 3). Sample solution (5 mL) was withdrawn at predetermined time intervals, filtered through a membrane filter, suitably diluted and analysed spectrophotometricaily. An equal amount o f fresh dissolution medium was replaced immediately after withdrawal of the test sample. The percentage drug dissolved at different time intervals was calculated using a regression equation generated from the standard curve.
Matrix erosion study
The matrix erosion study was carried out by the method suggested by Dhopeshwakar & Joel (1993) for establishing a correlation between drug release and matrix erosion. In brief, representative samples from each batch were subjected to erosion in a USP 23 basket apparatus (50 rev mm-1 , 37± 0-5°C , 900 mL distilled water, n = 3). The tablets were withdrawn at predetermined time intervals and dried in a hot-air oven at 75°C to a constant weight. The average matrix weight loss was calculated up to 12 h.
Tablet hydration study
To evaluate the water penetration and subsequent swelling characteristics, the increase in height and diameter o f the tablets were measured every hour up to 12 h by placing the tablet in a beaker containing 900 mL distilled water. The beaker was kept in a USP 23 paddle apparatus (50 rev min-1 ) at 3 7± 0-5°C (n = 3). The average equili brium degree of swelling (Q) was calculated from the radial and axial swelling ratio: Q = Vt/V0 = (Rt/Ro)2 x (It/Io). Vt and V0 are volumes, Rt and Ro are radii and It and Io are thickness at time t and time zero, respectively (Colombo et al 1990) .
Central composite design
M ost formulation studies involve variation o f one factor at a time, keeping other factors constant. Factorial designs enable all factors to be varied simultaneously, allowing quantification o f the effects caused by independent variables and inter actions between them. In fall factorial design, only a limited number o f factors can be investigated because an increase in the number o f factors markedly increases the number o f experiments to be carried out. The central composite design allowed us to evaluate three factors at five levels by preparing only twenty batches.
Preparation o f tablets (central composite design)
The required quantities of diltiazem HC1, modified guar gum (batch C, No. 100/120) and succinic acid (No. 100/120) were physically admixed. The blend was then lubricated with 2% w /w magnesium stearate and 1% w /w talc. The tablets were pre pared by direct compression on a rotary tablet press fitted with concave punches o f 9 mm diameter. The composition o f the twenty batches is shown in Table 2 .
Kinetics o f drug release
The method o f Bamba et al (1979) was adopted to decide the most appropriate model. The dissolution data of 20 batches were fitted to zero-order and Korseraeyer & Peppas (Mt/M a = kt") models. The results of jp-statistics were used for the selec tion of the most appropriate model. Non-linear regression analysis was carried out for refining the values of slope and intercept obtained by linear regression analysis.
Results and Discussion
The swelling capacity of the modified guar gum (11-3 ±0-2) was greater in magnitude than that of the untreated guar gum (6-2 ± 0-2); the swelling capacity of control guar gum was 5-9 ± 0 1 . No significant difference was found between the swelling capacity of untreated guar gum and that of control guar gum (tstat (1-16) < t^s^ (2-78)), but a significant difference was found between the swelling capacity of untreated guar gum and modified guar gum (tstat (22-64) > ^5,4) (2-78)). The results indicate that the difference m swelling characteristics of guar gum is a result of alkali treatment. The results of the swelling study of the eight batches are shown in Table 1 
(r = 0-8390, DF = 7, F = 3-17) From the numerical value of coefficients, it can be concluded that the factors Xx (time) and X3 (temperature) have a less pronounced effect on swelling capacity than factor X2 (NaOH concn). Therefore, the sample (batch C), prepared at a low level of temperature (60°C) and heating time (1 h) and high level of NaOH (1-5% w/v), was used for preparing the tablets of diltiazem HC1.
Preliminary trials
The tablets containing untreated guar gum, pre pared by the direct compression technique, were highly friable. Hence, the tablets of the preliminary batches were prepared by the wet granulation technique. The modified guar gum showed good direct compression characteristics. For comparative evaluation of dissolution, matrix erosion and tablet hydration, tablets containing untreated or modified guar gum were prepared by wet granulation in the preliminary trials.
Dissolution study
A good sustained-release dosage form must release the loading dose in the first hour (about 25%) and the remaining drug should be released at a rea sonably constant rate. The criterion of loading dose is generally fulfilled in matrix tablets by quick release of the drug present in the surface layer of the tablets. The drug release is then controlled by swelling, erosion of the matrix, or both.
The comparative drug release profile ( Figure 1 ) indicates that the criterion of loading dose was fulfilled by both the matrix tablets containing untreated guar gum and modified guar gum. The drug-release profile up to 7 h was comparable m both cases. However, in the terminal phase, a long tailing was observed with the matrix system con taining untreated guar gum (about 86% drug released after 12 h). With the untreated guar gum matrix, the core of the tablet remained dry even after 12 h exposure to the dissolution medium, whereas the tablets containing modified guar gum showed complete wetting during the dissolution test. This could be one reason for slower drug release in the terminal phase of the dissolution test. The difference and similarity equations are given in the US FDA (1997) guidelines for industry for dissolution testing of immediate-release products. The value of the similarity factor (fa) is equal to 100 when the two dissolution profiles are identical. The method was used here to observe the difference in dissolution. The f2 value for the drug release profile of the untreated and modified guar gum formulation was 56-9, which indicates that the difference is significant at an average difference of no more than 5% at any sampling time point. A value of >65 is necessary for similarity in dis solution profiles at 5% difference (Shah et al 1998) . Figure 2 shows that the tablets containing untreated guar gum and modified guar gum had almost identical weight loss during the test, suggesting a similar degree of erosion of the matrices. This finding was also supported by Student's r-test (tstat (249) < tent (i,H) (3*11)). However, the two types of tablet showed a different dissolution pattern. Thus, it may be concluded that good correlation does not exist between drug release and matrix erosion in this study. Slower drug release from untreated guar gum matrix tablets was observed due to incomplete wetting and gelling of the matrix. The complete wetting of modified guar gum tablets might have facilitated drug release by diffusion as well as by erosion mechanisms. Figure 3 shows the change in dimensions of the matrix tablets on hydration as a function of time. The fluid enters m the pores of the matrix and causes hydration of the gum when a tablet is immersed in the liquid medium. On hydration, the polymer chain of the gum undergoes transition from a glassy to rubbery state, which is manifested in the formation of gel. The hydrated gel erodes slowly and a new gel layer is then exposed. This process continues until the core of the matrix is completely wetted and erosion of the gel is not replenished with a new gel formation A slow diminution of the gel thickness then occurs until the whole matrix is completely eroded. Figure 3 reveals that a relatively higher degree of swelling was noticed for tablets containing mod ified guar gum than tablets containing untreated guar gum. The result of Student's /-test showed a significant difference m the degree of swelling between the tablets containing untreated guar gum and modified guar gum (t,taf (5-59) > tcnt{U2) (3) (4) (5) (6) ). This behaviour is probably due to the higher hydration rate of modified guar gum as compared with that of untreated guar gum. The slower rate of hydration of untreated guar gum is due to its poor rate of interaction coefficient which delays the complete gel layer formation. The slow water uptake rate also slows down the polymer swelling.
Matrix erosion study
Tablet hydration study
Optimization study
The problem of non-uniform and slow drug release with the untreated guar gum, particularly in the terminal phase, could be solved by modifying the guar gum. A uniform precision rotatable central composite design was adopted in this study to understand the importance of selected formulation variables. Low (90 mg) and high (180 mg) levels of modified guar gum were selected in the optimizing study. Two dose strengths, 90 and 180 mg, were selected as a low and high levels of diltiazem HC1, respectively. To investigate the effect of an acid ifying agent on drug dissolution, succinic acid was used at 0 mg (low) and 50 mg (high). Modified guar gum exhibited direct compression characteristics and hence the tablets were prepared by the direct compression technique m the optimization study.
The results of F-statistics revealed that no sig nificant difference was found between Weibull, Hixon-Crowel and Higuchi models. The values of slope and intercept of the Weibull model (Langenbucher 1972), determined by non-linear regression analysis, were used to calculate the attributes selected for the present optimization set, The ideal t63 2 and t80 (considering 25% drug release as a loading dose and 6-82% drug release per hour thereafter) are 396 and 544 min, respec tively, for a formulation that exhibits release up to 12 h The following constraints were chosen for the selection of batches: Y60<25% ; 55% < Y360 < 65%; 75% < Y54o < 85%; Y22o > 85%. The constraints set for te32 and t80 are 340 min < t63 2 < 460 min and 490 min < t80 < 6 1 0 min. 
Conclusion
This study demonstrates that alkali-treated guar gum can be used as a hydrophilic matrixing agent. The reaction conditions for the modification o f guar gum were optimized using a 23 factorial design The modified guar gum showed good direct compression characteristics and was found to be better than the untreated guar gum as a matrixing agent. The tablet formulation containing diltiazem HC1, modified guar gum and succinic acid was optimized using a uniform precision rotatable central composite design. The systemic formulation approach enabled us to develop modified-release diltiazem HC1 tablets using a rela tively inexpensive, naturally occurring material. ,S d,t h e ra tio o f th e m e a n p e rc e n ta g e o f dissolved d ru g ,a n d th e m e a n disso lu tio n tim e .T h e p e rc e n ta g e d iffe re n c e b e tw e e n th e te s t a n d re feren ce fo rm u la tio n s w as s m a ll.T h e d iffe re n c e b e tw e e n th e results o f tw o im m e d ia te -re le a s e c o m m e rc ia l fo rm u la tio n s w as large.
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olid dosage forms such as tablets and capsules continue to enjoy the highest market share despite advancements in other drug delivery systems. This status primarily re sults from the wide availability of the necessary raw ma terials, equipment, and technology. The importance of inten sive product testing of all dosage forms has increased in recent years because of an increased emphasis on validation.
Dissolution testing is critical because drug release from the solid dosage form after oral administration is a prerequisite for drug absorption and bioavailability. For sustained-release for mulations, drug dissolution is a key property of the product. Equally important is the retention of a drug's dissolution prop erties after storage. Ideally, a product would retain its dissolu tion characteristics from the time of manufacture to its expiry date. Pharmaceutical firms typically characterize the in vitro dissolution of a reference and a test product during formula tion development, preclinical studies, and dissolution stability studies. Dissolution testing also is used as a quality assurance tool during regular production and to meet regulatory re quirements. Manufacturers must voluntarily recall drug prod ucts that fail dissolution. To derive meaningful conclusions, cur rent practice evaluates the entire dissolution profile, compared with the earlier approach that used one time point (e.g., time required for 90% drug dissolution for a reference and a test product).
The primary factors that influence the dissolution rate of a drug are its physicochemical properties, product formulation, type of dosage form, the dissolution testing device, dissolution test parameters, and miscellaneous factors (1). Andreas discussed some critical process parameters that affect drug dissolution (2) . Several reports in the literature have discussed the comparison of dissolution data to establish statistical or pharmaceutical equivalence. Qureshi and McGilveray observed that -20-38% of the variability in the dissolution testing of furosemide tablets was not product-related (i.e., it was caused by the testing itself), while the remaining 62-80% variability was product-related (e.g., manufacturing or formulation) (3). They further concluded that high variability in drug dissolution testing would require wide tolerance standards (i.e., pharmacopeial standards). Polli et al. compared dissolution profiles of four bioequivalent meto- prolol tartrate tablets using analysis-of-variance-based, modelindependent, and model-dependent approaches (4). They con cluded that some metrics depended on the length of the disso lution profile and the sampling scheme. Rescigno proposed a bioequivalence index to measure the difference between a ref erence and a test formulation (5).
Moore and Flanner recently proposed a versatile, modelindependent m athem atical approach for calculating a dis similarity factor (/j) and a similarity factor (_/j) (6). The dis similarity factor /, is the average percentage difference over all time points in the amount of drug dissolved from the test for mulation compared with that dissolved from the reference for mulation. The dissim ilarity and sim ilarity equations were provided by FDA's guidance on the dissolution testing of im mediate-release solid oral dosage forms (7). Sathe and co workers examined a m odel-independent approach for per forming statistical analysis of dissolution data (8) . The approach accounts for the variance and covariance of the dissolution data sets. Tanigawara et al. reported that mean in vitro disso lution time (MDT) can be used as a tool for assessing in vitro drug release (9) . They correlated MDT with the parameters of several dissolution models. Anderson et al. concluded that it is easier to interpret dissolution efficiency than the corre sponding results of the fit factors / a n d /2 (10,11). Pillay and Fassihi concluded that results derived from application of-the similarity factorare superior to individual time points (e.g., tM and M D T^) in differentiating between overall release pat terns or borderline release profile differences (12) . All the methods just described have both advantages and dis advantages, and no one method is universally accepted. In gen eral, statistical methods are complicated, cumbersome, and re quire special computer programs (e.g., SAS [SAS Institute, Inc., Cary, NC] and SPSS (SPSS, Inc., Chicago, IL]). This article adds a novel and simple mathematical method to the existing array of methods for comparing dissolution profiles. The technique is an extension of the method of the ratio of area under the dis solution curve (4) . The ratio of area under the curve (AUC) is used in the proposed method as the dissolution efficiency (11). The method is especially useful when the dissolution process cannot be delineated by other techniques such as the zero-order, Weibull, Higuchi, or Makoid and Banaker models. The major advantages of the proposed method are simplicity, ease of inter pretation, and the feasibility of quantifying the results.
Materials and methods
Materials. Diltiazem HC1USP (Cadila Fiealth Care Private, Ltd., Ahmedabad, India) and guar gum IP (H.B. Gum Industries, Ltd., Kalol, India) were received as gift samples. Magnesium stearate IP and talc IP (JC's Reagent, Baroda, India) and suc cinic acid (E. Merck India, Ltd., Mumbai, India) were used as received. All other chemicals and solvents were of analytical grade.
Methods. Preparation of the sustained-release test form ulation.
The sustained-release test formulation was prepared by blending dil tiazem HC1 (90 mg), alkali-treated guar gum (60.5 mg), and suc cinic acid (5.625 mg). The blend was lubricated with 1% w/w talc and 2% w/w magnesium stearate. The tablets were prepared by direct compression on a 16-station rotary tablet press (Clit Jemkay Engineers, Private, Ltd., Ahmedabad, India) fitted with concave punches (7-mm diameter). Fifteen die cavities were blocked with solid stainless steel dies to facilitate the prepara tion of small batches. The method used to prepare the alkalitreated guar gum has been described elsewhere (13) .
Dissolution studies. The dissolution study of sustained-release formulations was performed on a reference tablet (Dilzem SR, Torrent Pharmaceutical, Ltd., Chhatral, India) and a test tablet, each containing 90 mg diltiazem HC1. The study was performed using a USP 23 paddle apparatus (model TDT-06 T, Electrolab, Mumbai, India) with deaerated distilled water (900 mL, 37 ± 0.5 °C) and a paddle rotation speed of 50 rpm. Samples (5 mL) were withdrawn at predetermined time intervals, filtered through a 0.45-p.m membrane filter, diluted suitably, and analyzed spectrophotometrically at 237 nm (UV-vis spectrophotom eter model U 2000, Hitachi, Tokyo, Japan). Fresh dissolution medium (5 mL) was added to maintain the volume. The absorbance val ues were transform ed :o concentration by reference to a stan dard calibration curve obtained experim entally (r = 0.9995, r = 0.9990).
To check the applicability o f the proposed factor Sd (see sec tion titled "M odel-independent m ethods"), the authors evalu ated two comm ercially available im m ediate-release products co n tain in g 30 mg o f d iltiazem HC1. D ilzem -30 (T o rren t Pharm aceutical) and D iltim e-30 (C adila C hem icals, Ltd., A hmedabad, India) were selected as the reference and the test form ulations, respectively. For the im m ediate-release p ro d ucts, the dissolution study was carried o u t in deaerated dis tilled water (900 mL, 37 ± 0.5 °C) using the USP 23 paddle apparatus (rotation speed = 100 rpm ). Figures 1 and 2 show the dissolution profiles o f th e su stain ed -and im m ediaterelease form ulations, respectively. M odel-independent methods. To determine the similarity and con com itant dissimilarity between the reference and test form ula tions, dissolution data were fitted to the fit factors (/, and f2) (6), two bioequivalence indices proposed by Rescigno (f, and f 2) (5), and a new factor, the similarity factor (Sd). Sd, the dif ference in similarity, is defined as
where n is the num ber ot data points collected during the in vitro dissolution test (tim e and p ercentage/am ount of drug dissolved) and AUCRt and AUCJt are the areas under the dis solution curves of the reference and test form ulations, respec tively, at tim e r. Table I presents the m ean values and corre sponding standard error (SE) o f various factors.
The authors perform ed the ratio test o f the percentage of drug dissolved. The mean percentage o f drug dissolved and its SE were estimated for each o f the two formulations being com pared at a particular sample time. The ratio of the m ean p er centage dissolved was an estimate of the mean ratio of the per centage of drug dissolved from the test formulation to that from the reference form ulation (i.e., mean o f test to m ean o f refer ence). The authors estimated the SE o f the mean ratio using the
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D elta m eth o d (14) . A ddi tionally, th e M D T was cal culated for each formulation (9) . The M D T provides a more accurate determination o f the drug release rate than does a tim e-point approach (e-g-> t50%>4/0%' o r '■ 90%)
R e s u l t s a n d d i s c u s s i o n T h e o r e t i c a l c o n s i d e r a t i o n o f S d .
To generate standard data for Sd, the authors assumed the dissolution data had a linear relationship between two sampling times because the AUC was calculated by the trapezoidal rule. The precision o f prediction increases as m ore data points are used to calculate Sd. W hen the dissolution curve of the test prod uct overlaps that of the reference product, the value o f the ex pression in the n um erator o f E quation 1 equals zero. Hence, the value o f Sd is zero. Table II Table II lists the data for the 95% confidence interval about the regression line. For ex ample, the authors are 95% confident that, for a 5% difference, the value o f the average absolute log(AL7C^/A!7Cr) will be be tween 0.0188 and 0.0235.
Because the relationship between the percentage difference and average absolute value of log(AL/C^/AI/Cj.) is linear, it is possible to quantitatively express the difference by linear interpolation. For example, if the average absolute value o f log(At/C^/A[7Cr) is equal to 0.06595, the percentage difference between the two dissolution profiles is 16.8. However, the relationship between the fit factor^ and the average difference between the reference and the test curves (in %) is nonlinear (correlation coefficient r = -0.9163 for data € 3 0 % difference). Hence, the linear interpolation technique is not applicable to the similarity factor jj.
C o m p a r i s o n o f s u s t a i n e d -r e l e a s e f o r m u l a t i o n s . The value o f f2 is 100 w hen the test and the reference profiles are identical and approaches zero as dissimilarity increases. FDA's Scale-Up and Postapproval Changes for Immediate-Release Dosage Forms (SUPAC-IR) specifies 50 as the threshold value for two disso lution profiles to be considered sim ilar (16) . The average dif ference between two dissolution profiles is 2, 5 ,10,15, or 20% for calculated f2 values o f 83,65,50,41, or 36, respectively (17) .
In this study, th e /2 value was 65.19 ± 1.24 (see Table I eating that the average difference between the two dissolution profiles was 5%. The / value is zero when the test and reference profiles are identical and increases proportionally with the dissimilarity be tween the two profiles. In this study / was 6.75 ± 0.48, which indicates reasonably good similarity between the test and ref erence formulations (see Table I ).
The Rescigno index £ is zero when two plasma concentra tion curves are identical and one when either formulation (ref erence or test) is not absorbed at all. When the two formula tions are not very dissimilar, £ and /, are quite close (5) . The values of and f 2 were 0.035 ± 0.003 and 0.038 ± 0.002, re spectively, which were close to zero and quite similar, indicat ing that the test and reference formulations were very similar (see Table I ). The value of Sd was 0.037 ± 0.003 (see Table I ). From the regression line generated for the percentage differ ence from 0 to 30%, the percentage difference between the test and reference formulations was 9.2.
To generate the data shown in Table I , individual dissolution profiles were matched according to identical dissolution kettle numbers (i.e., kettles 1-6 of each test formulation were matched with kettles 1-6 of each reference formulation). To validate the acceptance of the different factors, calculations were performed on mean dissolution data from each formulation. This step de creases the number of calculations, which is especially impor tant when performing the dissolution test using a minimum of 12 replicates (16). Pillay and Fassihi reported that the values of /, and f 2 were not statistically different when calculated using mean or individual dissolution data (12) . The respective per centage difference between two dissolution profiles was less when mean rather than individual dissolution data were used to calculate various factors (see Table I ).
In vitro dissolution data for tablets and/or capsules gener ally are presented as the cumulative amount of drug dissolved, the cumulative percentage of drug dissolved, or the amount of drug remaining to be dissolved as a function of time. The simi larity factor f 2 requires that the data be expressed as the per centage of drug dissolved. The equation for f 2 can be used to compare curves in which the average difference between the
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reference and the test formulations is <100. If the average dif ference between the two formulations is >100, the equation yields a negative value. In such cases, Moore and Flanner sug gest transforming the data (6). A negative f 2 value results when the drug from the reference formulation dissolves completely before dissolution from the test formulation begins (6) . In this case, the ratio of A U C rI A U C j becomes infinite and the value of Sd cannot be calculated. This condition, however, rarely oc curs in real practice. Using the proposed method, drug disso lution data can be expressed as an amount (e.g., in milligrams) or as a percentage at various sampling times -neither changes the Sd value appreciably. For example, for the sustained-release formulations, the value of Sd was 0.038 ± 0.003 and 0.037 ± 0.003 calculated using cumulative amount and cumulative per centage dissolved, respectively. The value of Sd was identical (0.023) when calculated using the mean cumulative amount or percentage released.
Comparison of immediate-release formulations. Table I presents the results of various factors. The value o f / 2 (14.79 ± 0.28) indicates that the two formulations were dissimilar. SUPAC-IR states that a value o f /2 between 50 and 100 suggests two dissolution profiles are sim ilar (16) . The value of the dis similarity factor/, (54.62 ± 0.75) indicates that the difference between the two dissolution profiles was high. The value of Sd (0.384 ± 0.009) confirms that the two immediate-release for mulations were dissimilar because, for a 30% difference in dis solved drug, the Sd value should be 0.1139. The difference in dissolution could have resulted from different solubilities of the coating agents in the dissolution medium. Notably, the ref erence product disintegrated after -10 m in while the test product slowly eroded during the test. This poor disintegra tion possibly could be attributed to strong binding between the granules. When mean dissolution data were used to cal culate different factors, no noticeable difference was found (see Table I ).
Ratio of mean percentage dissolved. Figures 3 and 4 illustrate the ratio of the mean percentage of drug dissolved (test formulation/ reference formulation) for sustained-and immediate-release formulations, respectively. If drug dissolution from the test for- mulation is identical to that from the reference formulation, the ratio of the mean percentage drug dissolved is one. For sustainedrelease formulations, this ratio was in the range of 0.833 ± 0.051 to 1.111 ± 0.030. Based on these results, the percentage differ ence between the dissolution profiles of the test and the refer ence formulations was small. For the immediate-release formu lations, the ratio was in the range of 0.261 ± 0.006 to 0.767 ± 0.008, indicating that the percentage difference was very large.
MDT. The ratio of the MDT of two identical formulations is one. For sustained-release formulations, the ratio of the aver age MDT of the test formulation (4.59 ± 0.04) to that of the reference formulation (4.75 ± 0.12) was 0.97, which indicates these formulations were quite similar. For immediaterelease formulations, the ratio of the average MDT of the test formulation (26.78 ± 0.33) to that of the reference formula tion (7.49 ± 0.17) was 3.58, indicating that the difference be tween these formulations was very large.
C o n c lu s io n
The authors' main objective was to apply a new method for comparing in vitro dissolution profiles, together with several existing approaches, with in vitro dissolution data sets. All of the adopted approaches (Le.,fv f2, (q, £2, and Sd) except the ratio of percentage dissolved simply comment on the difference be tween two curves w ithout determining whether the test for mulation has a higher or lower amount dissolved than the ref erence formulation. However, unlike single-point approaches that do not adequately characterize the entire dissolution pro file (e.g., t^) , these factors do consider the whole dissolution profile. These approaches yielded results that possibly can serve as objective and quantitative metrics for comparing entire dis solution profiles.
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The primary advantages of the proposed method are sim plicity and flexibility because the data can be expressed either in the am ount of drug dissolved or the percentage of drug dis solved. Another major advantage is that linear interpolation can be used to accurately express the results. The proposed method can be used to assess inter-or intralot variation in dissolution. This method can be further tested along with the existing array of methods available for comparing dissolution data. A b s t r a c t a simple mathematical method to express the deviation in release profile o f a test product following Higuchi's kinetics from an ideal Higuchi release profile was developed. The method is based on calculation of area under the curve (AUC) by using the trapezoidal rule. The precision o f prediction depends on the number of data points. The method is exemplified for 2 dosage forms (tablets o f diltiazem HC1 and microspheres of diclofenac sodium) that are designed to release the drug over a 12-hour period. The method can be adopted for the formulations where drug release is incomplete (<100%) or complete (100%) at last sampling time. To describe the kinetics o f drug release from the test fonnulation, zero-order, first-order, Higuchi's, Hixson-Crowell's, and Weibull's models were used The criterion for selecting the most appropriate model was based on the goodness-of-fit test. The release kinetics of the tablets and microspheres were explained by the Higuchi model. The release profiles o f the test batches were slightly below the ideal Higuchi release profile. For the test products, oaserved percentage deviation from an ideal Higuchi profile is less than 16% for tablets and less than 11% for microspheres. Tire proposed method can be extended to tire modified release formulations that are designed to release a drug over 6, 18, or 24 hours. If the data points are not evenly separated, the ideal drug release profile and AUC are calculated according to the specific sampling time. The proposed method may be used for comparing formulated products during the research ar.d development stage, for quality control of the products, or for promoting products by comparing performance o f the test product with that o f the innovator's product.
INTRODUCTION
Ideally, controlled drug-delivery systems should deliver the chug at a controlled rate over a desired duration. The primary objectives o f the controlled drug-delivery systems are to ensure safety and to improve efficacy of drags, as well as to improve patient compliance. O f the approaches known for obtaining controlled drag release, hydrophilic matrix is recognized as the simplest and is the most widely used. Hydrophilic matrix tablets swell upon ingestion, and a gel layer forms on the tablet surface. This gel layer retards further ingress o f fluid and subsequent drag release. It has been shown that in the case o f hydrophilic matrices, swelling and erosion o f the polymer occurs simultaneously, and both o f them contribute to the overall drag-release rate [1] , It is well documented that drag release from hydrophilic matrices shows a typical time-dependent profile (ie, decreased drug release with time because o f increased diffusion path length) [2, 3] . This inherent limitation leads to first-order release kinetics.
Many controlled-release products are designed on the principle o f embedding the drag in a porous matrix Liquid penetrates the matrix and dissolves the drag which then diffuses into the exterior liquid [4] Wiegand and Taylor [5] and Wagner [6] showed that the percentage o f drug released versus time data for many controlled-release preparations reported in the literature show a linear apparent first-order rate. Higuchi tried to relate the drug release rate to the physical constants based on simple laws o f diffusion. Release rate from both a planar surface and a sphere was considered. The analysis suggested that m the case of spherical pellets, the time required to release 50% of the drag was normally expected to be 10% of the time required to dissolve the last trace o f solid drug in the center of the pellet [7] .
Higuchi [7, 8] 
Where, Q, is the amount of drug released m tune t, D is the diffusion coefficient, S is the solubility of drug in the dissolution medium, e is the porosity, A is the chug content per cubic centimeter of matrix tablet, and k.n is the release rate constant for the Higuchi model.
Considerable attention has been given to describing drug release by the Higuchi equation To the best of our knowledge, no research has been reported that quantifies the percentage deviation from the ideal Higuchi release pattern. In the present study, a simple mathematical method is proposed to quantitatively express the deviation from Higuchi kinetics. The method is exemplified for 2 dosage forms (tablets and microspheres) that are designed to release drag over a 12-hour period. It may also be extended to other systems.
MATERIALS AND METHODS
Materials
Diltiazem HC1 USP and hydroxypropyl methylcellulose (HPMC K4M) were received as gifts from Cadila Health Care Pvt Ltd (Ahmadabad, India) Guar gum IP (5400-cPs viscosity, 2% wl/vol aqueous solution) was received as a gift from H. B. Gum Industries Ltd (Kalol, India). Magnesium stearate IP, talc IP (JC's Reagent, Baroda, India) and succinic acid (E. Merck Ltd, Mumbai, India) were used as received.
All other solvents and chemicals were o f analytical grade. Deionized double-distilled water was used throughout the study.
Assay
Aqueous solutions o f diltiazem HC1 in distilled water were prepared and the absorbances were measured at 237 nm using a Hitachi U-2000 UV-VIS double beam spectrophotometer (Hitachi, Tokyo, Japan)f91. An equation was generated by fitting a weighted linear regression model to the data obtained m triplicate (n = 3)1101.
Tablet preparation
Diltiazem HC1 (43.18% wt/wt), alkali-treated guar gum (43.18% wt/wt), and succinic acid (10.64% wt/wt) were physically admixed. The blend was then lubricated with 1% wt/wt talc and 2% wt/wt magnesium stearate. The method for preparation of alkali-treated guar gum is reported in our previous work [ i l j • The tablets were prepared by direct compression on a 16-station rotary tablet press equipped with concave punches o f 9-mm diameter Fifteen die cavities were blocked with stainless steel solid blocks The batch size was 250 tablets. The compression force was adjusted so that the crushing strength o f the tablets was m the range o f 50 ± 10 N. The average weight and the drug content o f the tablets were 375 mg and 162 ± 5 mg respectively.
Dissolution study
In vitro release o f diltiazem HC1 from the matrix tablets was measured according to the USP XXIII paddle apparatus (Electrolab, model TDT-06 T, Mumbai, India) at 37°C ± 0 5°C and at 50 rpm using 900 mL o f distilled water as a dissolution medium (n = 3). Samples (5 mL) were withdrawn at predetermined time intervals, filtered through a 0.45 pm membrane filter, diluted suitably (absorbance in the normal range o f 0.2 to 0.8), and analyzed spectrophotometncally An equal volume o f fresh dissolution medium, maintained at the same temperature, was added after withdrawing each sample to maintain the volume. Percentage o f drug dissolved at different time intervals was calculated using the equation generated from the standard curve. 
Kinetics o f drug release
To describe the kinetics of the drug release from the test formulation, mathematical models such as zero-order, firstorder, Higuchi's, Hixson-Croweli's, and Weibull's models were used. The criterion for selecting the most appropriate model was based on a goodness-of-fit test [121.
THEORETICAL CONSIDERATION
The fust step is to calculate the theoretical percentage of drug released using the Higuchi equation ( 
AUC, t hr, 0% deviation" *H xn
Where, kH, t, and n are Higuchi rate constant, tune, and difference between two successive sampling time points respectively. The AUC for a % deviation from the Higuchi release profile is represented by equation 4.
AUC. t hr, a% deviation
a 100 
For the 12- It is important to note that equation 11 is applicable for the ideal' 12-hour Higuchi release profile only. The values o f slope for the different Higuchi release profiles for n = 1 can be generated using equation 9 ( 
R E S U LTS A N D D IS C U S S IO N
The drug-release profile o f the tablets containm; untreated guar gum showed a tailing effect in th terminal phase, which was not observed in the tablet containing alkali-treated guar gum. The purpose o adding succinic acid was to investigate the influenc o f microenvironmental pH. The details o f this effec are discussed in our earlier study rill.
The percentage diltiazem HC1 released as a functio of time from the prepared tablet is shown in Table 1 The dissolution data were fitted to the differei models ( Table 2 , tl deviation from the ideal 12-hour Higuchi releai profile is less than 16% at any time point.
The proposed method is also exemplified f< microspheres o f diclofenac sodium. The method i preparation o f microspheres (best batch -No. 9) given in our earlier work [13] . The percentage ■ diclofenac sodium released as a function o f tm from the microsphere is shown in Table 2 ; tl deviation from the ideal 12-hour Higuchi relea profile calculated using the proposed method is le than 11% at any time point. The model illustrated Table 3 reveals that the release o f diclofenac sodiu from the microspheres follows Higuchi's equation. V indicates square of correlation coefficient, SSR, sum of square residuals.
The comparative release profiles of the ideal and the test batches are shown in Figure 3 for tablets and Figure 4 for microspheres. The release profiles of the test batches were slightly below the ideal Higuchi release profile. The values of SSR also indicate that there is some difference between the ideal and the testrelease profiles and this difference can be calculated by the proposed method.
For a 12-hour controlled release formulation, ideally the percentage chug released at 12 hours should be 100. If the percentage chug released at 12 hours is less than 100 (ie, 84%), one should generate an ideal release profile accordingly. If the data points are not evenly separated, the ideal drug release profile and AUCs are generated according to the sampling time points of dissolution study of the test batch. Then, for a particular time point, percentage deviation can be calculated using equation 11, where n is the difference between 2 successive time points. Tire application of our method, for time points that are not evenly separated, is shown in Table 4 .
In summary, a simple mathematical model is proposed for the comparison of formulated products during the research and development stage, for quality control of matrix tablers, or for promoting products by comparing the performance of the test product with that of the innovator's product.
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